Topic: Genetic Data

Genetic testing company 23andMe has filed for bankruptcy protection following years of financial challenges, leading CEO Anne Wojcicki to resign. The California Attorney General has urged customers to request the deletion of their data and the destruction of genetic samples to prevent them from being sold during the liquidation process. This development follows decade-long warnings from privacy advocates regarding the long-term security of personal DNA databases.

The financial collapse of 23andMe is analyzed, with its stock losing 99.9% of its value and its board of directors resigning. Concerns are raised about the fate of the genetic data of 14 million customers, which is not protected by HIPAA. The data is currently being shared with GlaxoSmithKline (GSK) for pharmaceutical research, leading to fears that "anonymous" genetic information could eventually be weaponized or sold.

Los Angeles County Sheriff Alex Villanueva announced his department will stop using Fulgent Genetics for COVID-19 testing. He cites FBI warnings regarding the company's ties to the Chinese Communist Party and concerns over the use of genetic data for research.

The End User License Agreement (EULA) for AncestryDNA is scrutinized for clauses that grant the company a perpetual, royalty-free, worldwide license to use a customer's DNA data. The discussion highlights that after three years, users may lose certain claims to the ownership of their test results while the company retains usage rights.

The discussion explores the technical side of genetic data using SNPedia, an open-source database of single-nucleotide polymorphisms (SNPs). The hosts argue that while companies like 23andMe provide "recreational data," the actual predictive value for most diseases is low because many conditions lack a strong genetic component. They mention the Promethease software as a DIY alternative for analyzing raw genomic data.